ATE521621T1 - Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans - Google Patents

Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans

Info

Publication number
ATE521621T1
ATE521621T1 AT05814016T AT05814016T ATE521621T1 AT E521621 T1 ATE521621 T1 AT E521621T1 AT 05814016 T AT05814016 T AT 05814016T AT 05814016 T AT05814016 T AT 05814016T AT E521621 T1 ATE521621 T1 AT E521621T1
Authority
AT
Austria
Prior art keywords
single strand
desoxynucleotides
adjuvants
cpg
vaccine
Prior art date
Application number
AT05814016T
Other languages
English (en)
Inventor
Liying Wang
Musheng Bao
Yongli Yu
Original Assignee
Changchun Huapu Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200410096082 external-priority patent/CN1781929A/zh
Priority claimed from CN 200410096083 external-priority patent/CN1781930A/zh
Application filed by Changchun Huapu Biotechnology Co Ltd filed Critical Changchun Huapu Biotechnology Co Ltd
Application granted granted Critical
Publication of ATE521621T1 publication Critical patent/ATE521621T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05814016T 2004-11-29 2005-11-29 Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans ATE521621T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN 200410096082 CN1781929A (zh) 2004-11-29 2004-11-29 含CpG单链脱氧核苷酸作为狂犬疫苗的佐剂
CN 200410096083 CN1781930A (zh) 2004-11-29 2004-11-29 含CpG单链脱氧核苷酸作为乙型肝炎病毒疫苗的佐剂
PCT/CN2005/002047 WO2006056142A1 (en) 2004-11-29 2005-11-29 Cpg single-strand deoxynucleotides for use as adjuvant

Publications (1)

Publication Number Publication Date
ATE521621T1 true ATE521621T1 (de) 2011-09-15

Family

ID=36497749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05814016T ATE521621T1 (de) 2004-11-29 2005-11-29 Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans

Country Status (5)

Country Link
US (2) US20080003232A1 (de)
EP (1) EP1829887B1 (de)
JP (1) JP2008521385A (de)
AT (1) ATE521621T1 (de)
WO (1) WO2006056142A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EP2575878B1 (de) * 2010-05-28 2018-06-13 Zoetis Belgium S.A. Impstoffe mit cholesterin und cpg als einzige adjuvans-träger moleküle
EP2471926A3 (de) * 2010-12-30 2012-07-11 Intervet International BV Immunstimulierende Oligodeoxynukleotide
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
JP6312123B2 (ja) * 2013-11-19 2018-04-18 国立大学法人京都大学 細胞判定方法、細胞判定装置及び細胞判定プログラム
EP3164113B1 (de) 2014-06-04 2019-03-27 Exicure, Inc. Multivalente freisetzung von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen
CN105214083A (zh) * 2014-06-26 2016-01-06 长春华普生物技术有限公司 含有CpG寡核苷酸的药物组合物
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
CN115252772A (zh) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
CN114796476B (zh) * 2021-09-24 2024-10-11 中国医学科学院医学生物学研究所 一种亚单位疫苗新型核酸佐剂系统及其应用
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN114577954B (zh) * 2022-05-09 2022-08-02 北京生物制品研究所有限责任公司 检测吸附型疫苗中CpG ODN含量的方法
WO2024245358A1 (zh) 2023-05-30 2024-12-05 四川三叶草生物制药有限公司 冠状病毒疫苗组合物、方法及其使用
CN121464149A (zh) 2023-06-07 2026-02-03 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE275727T1 (de) 1999-04-29 2004-09-15 Coley Pharm Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
CN100486987C (zh) 2003-03-05 2009-05-13 长春华普生物技术有限公司 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸
CN100439386C (zh) 2003-03-05 2008-12-03 长春华普生物技术有限公司 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
RU2351362C2 (ru) * 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
CN1280303C (zh) 2003-05-28 2006-10-18 长春华普生物技术有限公司 人工合成的含CpG单链脱氧寡核苷酸及其抗SARS病毒作用
ATE502949T1 (de) * 2003-07-25 2011-04-15 Changchun Huapu Biotechnology Co Ltd Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen

Also Published As

Publication number Publication date
EP1829887B1 (de) 2011-08-24
JP2008521385A (ja) 2008-06-26
US20080003232A1 (en) 2008-01-03
US20090155303A1 (en) 2009-06-18
WO2006056142A1 (en) 2006-06-01
EP1829887A4 (de) 2008-06-25
US7745598B2 (en) 2010-06-29
EP1829887A1 (de) 2007-09-05

Similar Documents

Publication Publication Date Title
EP1829887A4 (de) Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
LU91778I2 (fr) Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
SI1951296T2 (sl) Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom
ATE396739T1 (de) Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
ATE426412T1 (de) Adjuvante influenza-vakzine
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
WO2007024941A3 (en) Polyvalent vaccine
DE60239594D1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung
GB2386072A (en) Novel vaccine
AU2001292610A1 (en) Genetically engineered co-expression dna vaccines, construction methods and uses thereof
WO2003066094A3 (en) Hepatitis b vaccines
PL2578229T3 (pl) Zmniejszenie potencjalnego zagrożenia jatrogennego związanego z antygenami w szczepionce
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
EA200301151A1 (ru) Вакцина против натуральной оспы
DK1606391T3 (da) Virulent systemisk felint calicivirus
GB2444676A (en) Adjuvanted vaccine
WO2007028985A3 (en) Adjuvanted vaccine
ATE431745T1 (de) Ltb4 als adjuvans für impfstoffe
UA91203C2 (ru) Новая фармацевтическая композиция, применимая для вакцин
AR056296A1 (es) Uso de vacuna de adn en combinacion con una vacuna convencional para vencer la interferencia de inmunogeno
CY1114309T1 (el) Εμβολιο ροταϊου

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties